fda
Five committees, 619 accidents: Canal Road remains a death trap
Unplanned entry points, access routes blamed
FDA 警告 GLP-1 减肥药可能增加突然失明风险
FDA 周一表示，GLP-1 药物生产商须在产品标签上增加一项可能导致突然失明的警示。被称为非动脉炎性前部缺血性视神经病变(nonarteritic anterior ischemic optic neuropathy，NAION)的眼部疾病会影响视神经——负责将信号从眼睛传输至大脑的神经。当流向视神经的血液减少或受阻…
Over Before it Begins
Haven't you heard? Myke had COVID.
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
The risk appears small and data is mixed, but FDA wants patients to be aware.
GLP-1 drugs taken by 30 million Americans now carry an FDA warning for a rare ‘stroke of the eye’ that can cause vision loss
The data on which the FDA’s warning is based suggests a real but low risk of NAION for people taking GLP-1 medications.
RFK Jr.’s HHS is letting pharmacies sell 6 unproven peptides like the ‘Wolverine stack’ — and no regulator will check what’s in them
In July 2026 the committee voted 8-6 to expand access to six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
두경부암·췌장암… 말기 환자 위한 신약 잇따라
（摘要暂无, 请查看原文）
Ozempic e Wegovy, nuovo allarme dell’Fda: questi farmaci dimagranti possono far perdere la vista?
I farmaci utilizzati per combattere il diabete di tipo 2 e favorire la perdita di peso finiscono sotto L'articolo Ozempic e Wegovy, nuovo allarme dell’Fda: ques…
